Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

WBP2 and HER2 act as co-prognostic factors to stratify patients for treatment

A patient and prognosis technology, applied in the direction of analytical materials, biomaterial analysis, instruments, etc.

Active Publication Date: 2021-02-09
NAT UNIV OF SINGAPORE
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, not all patients with HER2-positive cancers respond to treatment, and some HER2-positive cancers are self-limited even without treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • WBP2 and HER2 act as co-prognostic factors to stratify patients for treatment
  • WBP2 and HER2 act as co-prognostic factors to stratify patients for treatment
  • WBP2 and HER2 act as co-prognostic factors to stratify patients for treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0099] In an analysis involving more than 200 clinical samples (n=221), the combination of WBP2 and HER2 was found to be more powerful than WBP2 or HER2 alone in predicting poorer overall survival and disease-free survival (see Table 3 and figure 1 ). Reference only measures HER2-positive and HER2-negative ( figure 1 C and 1D) and measure the stratification of HER2-negative patients with low WBP2 levels, HER2-negative patients with high WBP2 levels, HER2-positive patients with low WBP2 levels, and HER2-positive patients with high WBP2 levels, see The difference is bigger. For example, with reference to HER2-negative patients with low WBP2 levels, the odds of overall survival in HER2-positive patients with high WBP2 levels were about 4.5-fold lower, and in HER2-positive patients with low WBP2 levels, the odds of overall survival were about 1.7-fold lower; and HER2-positive patients had an approximately 2.6-fold higher chance of relapse, while HER2-positive patients with low W...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for prognosing overall survival, cancer recurrence, or treatment response in a cancer patient, the method comprising: (a) examining a sample from the patient to determine that the patient is human epidermal growth factor receptor 2 (HER2) positive or negative; and (b) measuring WW domain binding protein 2 (WBP2) levels in said patient sample, wherein the results in step (a) and the results in step (b) provide the patient with overall survival, cancer Prognosis of relapse or response to treatment. The invention also provides kits for carrying out the methods of the invention.

Description

technical field [0001] The present invention relates to methods, systems and kits for the prognosis of cancer, especially breast cancer. The present invention also relates to the stratification of patient populations for cancer treatment, particularly breast cancer treatment. The present application also relates to the identification of cancer markers in methods, systems and kits for the prognosis of cancer, especially breast cancer. Background technique [0002] The following discussion of the background to the invention is intended to facilitate an understanding of the invention. It should be understood, however, that the discussion is not an acknowledgment or admission that any of the material referred to was published, known or part of the common general knowledge in any jurisdiction as at the priority date of the application. [0003] Breast cancer is the second most common type of cancer worldwide and one of the most common causes of cancer death in humans. The dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574
CPCG01N33/57415G01N2333/71G01N2800/52G01N2800/54G01N2333/4703
Inventor 林允斌
Owner NAT UNIV OF SINGAPORE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com